# Anthem Biosciences Limited (ANTHEM)

> ANTHEM closed at ₹829.90 on 30 Oct 2026, trailing P/E 81.2, market cap ₹46,755 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Anthem Biosciences Limited (NSE: ANTHEM) closed at ₹829.90 on 30 Oct 2026, +9.5% over one year, against a 52-week range of ₹579.15 – ₹977.55.

In the quarter ended 30 Jun 2026 (consolidated, filed 21 Jul 2026) it reported revenue of ₹418 cr and net profit of ₹120 cr, a 28.7% net margin; revenue fell 22.6% and profit fell 22.4% year on year.

On four consecutive filed quarters its trailing P/E is 81.2.

From the balance sheet dated 31 Mar 2026: return on equity 15.8%, ROCE 18.8%, debt-to-equity 0.02.

Against 65 Healthcare peers on NSE: Net margin higher than 95% of 63 sector peers; PBT margin higher than 90% of 63 sector peers; ROE higher than 62% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹829.90 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -6.3% / +12.2% / +9.5% |
| 52-week low – high | ₹579.15 – ₹977.55 |
| Market capitalisation | ₹46,755 cr |
| Trailing P/E | 81.2 |
| Price / book | 15.37 |
| EV / EBITDA | 50.2 |
| Earnings yield | 1.2% |
| TTM EPS | ₹10.22 |
| TTM net profit | ₹576 cr |
| Quarter revenue | ₹418 cr |
| Quarter net profit | ₹120 cr |
| Net margin | 28.7% |
| Revenue growth (YoY) | -22.6% |
| Profit growth (YoY) | -22.4% |
| Return on equity | 15.8% |
| ROCE | 18.8% |
| Debt / equity | 0.02 |
| Current ratio | 5.54 |
| Free cash flow | ₹633 cr |
| Average daily turnover (50 days) | ₹42.8 cr |

## Questions

### What is the P/E ratio of Anthem Biosciences Limited?

Anthem Biosciences Limited's trailing P/E is 81.2, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026.

### What were Anthem Biosciences Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Anthem Biosciences Limited reported revenue of ₹418 cr and net profit of ₹120 cr (consolidated), filed with the exchange on 21 Jul 2026.

### What is Anthem Biosciences Limited's ROE?

Return on equity is 15.8% based on the balance sheet dated 31 Mar 2026.

### Does Anthem Biosciences Limited have debt?

Debt-to-equity is 0.02 on the balance sheet dated 31 Mar 2026.

### What is ANTHEM's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, ANTHEM traded between ₹579.15 and ₹977.55.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/ANTHEM

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._